DEFA14A: Avadel & Alkermes Boost Acquisition Deal to $22.50/Share

Avadel Pharmaceuticals and Alkermes plc have amended their acquisition agreement, increasing the offer to up to $22.50 per share, with Avadel's Board reaffirming its recommendation for Alkermes.

Summary

• Avadel Pharmaceuticals plc and Alkermes plc entered into an amendment to their previously announced Transaction Agreement dated October 22, 2025, to reflect an increased offer.
• Alkermes will now acquire Avadel for up to $22.50 per ordinary share.
• The offer includes $21.00 per ordinary share in cash at closing.
• A potential additional cash payment of $1.50 per share is contingent upon final U.S. Food and Drug Administration (FDA) approval of LUMRYZ for the treatment of idiopathic hypersomnia in adults by the end of 2028.
• The Avadel Board considered an unsolicited proposal from H. Lundbeck A/S on November 13, 2025, but determined it no longer constitutes a 'Company Superior Proposal'.
• The Board found Alkermes' increased offer superior due to the CVR milestone being 'more likely to be achieved' compared to Lundbeck's proposal, despite identical cash consideration.
• Avadel's Board reaffirms its recommendation in support of the acquisition by Alkermes, and the amended transaction agreement remains in full effect.

Sentiment

Score: 8

Explanation: The filing announces an increased acquisition offer and reaffirms the Board's recommendation, indicating a positive outcome for shareholders, despite the contingent nature of part of the payment.

Positives

• The acquisition offer from Alkermes was increased to up to $22.50 per ordinary share, providing enhanced value for shareholders.
• Avadel's Board reaffirms its recommendation for the Alkermes acquisition, signaling confidence in the deal's terms and strategic fit.
• The Contingent Value Right (CVR) milestone in Alkermes' offer is deemed 'more likely to be achieved' than the CVR in the competing Lundbeck proposal, increasing the probability of the full $22.50 per share payout.

Negatives

• The additional $1.50 per share is contingent upon FDA approval of LUMRYZ for idiopathic hypersomnia by the end of 2028, introducing an element of uncertainty to the total acquisition value.
• The company expects continued attention from external parties, which could potentially be a distraction for management and employees during the transition period.

Risks

• The ability of the parties to consummate the acquisition in a timely manner or at all.
• The satisfaction (or waiver) of conditions to the consummation of the acquisition, including with respect to the approval of Avadel shareholders and required regulatory approvals.
• The potential impact of the unsolicited proposal from Lundbeck or the possibility that more competing offers may be made.
• Potential delays in consummating the acquisition.
• The ability of Avadel to timely and successfully achieve the anticipated benefits of the acquisition.
• The impact of health pandemics on the parties' respective businesses and the actions the parties may take in response thereto.
• The occurrence of any event, change or other circumstance or condition that could give rise to the termination of the transaction agreement.
• The effect of the announcement or pendency of the acquisition on Avadel's business relationships, operating results and business generally.
• Costs related to the acquisition.
• The outcome of any legal proceedings that may be instituted against the parties or any of their respective directors or officers related to the transaction agreement or the acquisition.
• The contingent $1.50 per share payment is dependent on final U.S. Food and Drug Administration approval of LUMRYZ for the treatment of idiopathic hypersomnia in adults by the end of 2028.

Future Outlook

The acquisition is expected to close, subject to Avadel shareholder approval and required regulatory approvals. The company anticipates continued external attention but emphasizes maintaining business as usual and executing priorities. The contingent $1.50 per share payment is tied to future FDA approval of LUMRYZ for idiopathic hypersomnia by the end of 2028.

Management Comments

• "Today we issued an announcement confirming that on November 18, 2025, Avadel Pharmaceuticals plc (Avadel) and Alkermes plc (Alkermes) entered into an amendment to the previously announced Transaction Agreement dated October 22, 2025, to reflect the terms of an increased offer."
• "The Avadel Board, in consultation with financial and legal advisors, gave due consideration to the unsolicited proposal it received from H. Lundbeck A/S on November 13, 2025 (the Lundbeck Proposal) to acquire Avadel."
• "After carefully assessing the relative benefits and risks of both the Lundbeck Proposal and Alkermes increased offer, the Avadel Board determined that the Lundbeck Proposal no longer constitutes a Company Superior Proposal as defined in our amended transaction agreement with Alkermes."
• "In light of the identical cash consideration proposed by both Alkermes and Lundbeck, the Avadel Board determined the terms of the CVR in Alkermes increased offer were superior to the terms of the CVR included in the Lundbeck Proposal, as the CVR milestone in Alkermes increased offer is more likely to be achieved."
• "Avadels Board reaffirms its recommendation in support of the acquisition by Alkermes and the Alkermes transaction agreement, as amended, remains in full effect."
• "It continues to be business as usual for all of us at Avadel. The most important thing we can all do is execute our priorities as we always have and continue to demonstrate the strength of the Avadel team and our capabilities."
• "We expect the attention Avadel has been receiving from external parties will continue, and it is important for us to speak with one voice."

Industry Context

This announcement reflects ongoing consolidation and strategic M&A activity within the pharmaceutical sector, particularly for companies with promising drug candidates like LUMRYZ. The competitive bidding process, involving an unsolicited proposal from H. Lundbeck A/S, highlights the perceived value of Avadel's assets and pipeline, driving up the acquisition price.

Comparison to Industry Standards

• The acquisition price of up to $22.50 per share, including a Contingent Value Right (CVR), is a common structure in pharmaceutical M&A, especially when a key asset (LUMRYZ for idiopathic hypersomnia) is awaiting a significant regulatory milestone.
• The competitive bidding scenario, where Lundbeck made an unsolicited proposal, is typical in the industry for attractive targets, often leading to increased offers from the initial acquirer, as seen with Alkermes.
• The Board's decision to favor Alkermes' CVR due to a higher likelihood of achieving the milestone (FDA approval by end of 2028) demonstrates a focus on the probability-weighted value of contingent payments, a standard practice in valuing such deals.

Corporate Governance

Legal Proceedings

• Potential legal proceedings that may be instituted against the parties or any of their respective directors or officers related to the transaction agreement or the acquisition.

Stakeholder Impact

• Shareholders: Potential for increased value from the acquisition, up to $22.50 per share, subject to CVR conditions. Will need to vote on the acquisition.
• Employees: Instructed to continue business as usual and to direct external inquiries to investor relations, indicating a period of transition and potential integration post-acquisition.
• Customers/Patients: Continued focus on serving patients, particularly those who may benefit from LUMRYZ.
• Regulatory Bodies (FDA, SEC, Irish Takeover Panel): Involved in the approval process for LUMRYZ and the acquisition itself, ensuring compliance with securities and takeover rules.

Next Steps

• Avadel will file a definitive proxy statement (including the scheme document) with the SEC.
• The definitive proxy statement will be sent to Avadel's shareholders for voting on the acquisition.
• Shareholder meetings will be held to approve the acquisition.
• The acquisition will be implemented by means of an Irish High Court-sanctioned scheme of arrangement.
• Avadel employees are expected to continue executing business priorities.
• Potential FDA approval of LUMRYZ for idiopathic hypersomnia by the end of 2028 for the CVR payment.

Key Dates

Recommendation

The increased acquisition offer from Alkermes, coupled with the Avadel Board's strong reaffirmation of the deal and its assessment that Alkermes' CVR is more likely to be achieved than a competing offer, presents a compelling value proposition for shareholders. The cash component provides immediate certainty, and the contingent payment offers upside tied to a specific, achievable regulatory milestone. This indicates a favorable outcome for investors holding Avadel shares.

Keywords

Avadel Pharmaceuticals, Alkermes, acquisition, merger, M&A, LUMRYZ, FDA approval, idiopathic hypersomnia, contingent value right, CVR, H. Lundbeck A/S, proxy statement, SEC filing